Possible new role for angiotensin-converting enzyme inhibitors in treating glomerulonephritis
AbstractSerum transforming growth factor-beta [TGF-beta1] production was estimated for 10 patients with essential hypertension, 12 patients with glomerulonephritis [5 hypertensive and 7 normotensive] and 10 healthy controls. The glomerulonephritis group received angiotensin-converting enzyme inhibitor captopril 25-75 mg/day for 4 weeks. Blood urea, serum creatinine, 24-hour urinary protein and serum TGF-beta1 were then re-estimated. Urea and creatinine were significantly higher in the hypertension and glomerulonephritis groups than in the controls and also higher in the glomerulonephritis group than the hypertension group. TGF-beta1 was significantly higher in the glomerulonephritis groups than in the control and hypertension groups. TGF-beta1 and 24-hour urinary protein were significantly reduced in the glomerulonephritis group
Soliman, A.R., El Meligi, A.A., El Semari, M., El Shemi, M. & Mahmoud, H. (2003). Possible new role for angiotensin-converting enzyme inhibitors in treating glomerulonephritis. http://www.who.int/iris/handle/10665/119290
EMHJ - Eastern Mediterranean Health Journal, 9 (3), 399-406, 2003
MetadataShow full item record
Showing items related by title and MeSH subject.